Fisher & Paykel Healthcare stock (NZFAPE0001S2): Shares slip 0.38% to $34.15 NZD

Fisher & Paykel Healthcare Corp Ltd shares fell 0.379% on Wednesday, May 13, 2026, closing at $34.15 NZD from $34.28, according to StockInvest.us as of 05/13/2026. The stock contributed to the NZX50's 0.1% drop to 13,063.06, with trading volume reaching 216,392 shares worth $7.5 million NZD, per NZX as of 05/13/2026. Open was $34.30, high $34.535, low $33.95.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Fisher & Paykel Healthcare: core business model

Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets products for airway management, acute respiratory care and obstructive sleep apnea treatment. The company focuses on innovative humidification and oxygenation technologies used in hospitals and home settings worldwide. Its portfolio includes interfaces, ventilators and consumables that support noninvasive ventilation.

Headquartered in Auckland, New Zealand, the firm operates globally with manufacturing in New Zealand and Mexico. It serves critical care, anesthesia and sleep therapy markets, emphasizing patient outcomes through proprietary humidification systems. US investors note its role in the medtech sector, with products integrated into American healthcare systems.

Main revenue and product drivers for Fisher & Paykel Healthcare

Key revenue comes from consumables like circuits and masks, which generate recurring sales due to single-use nature. Hospital products for acute care represent a major driver, bolstered by demand for noninvasive ventilation post-COVID. The sleep therapy segment, including the Evo platform, targets home care markets.

As of the latest NZX data on May 13, 2026, market capitalization stood at $20.6 billion NZD, with P/E ratio of 47.14 and EPS of $0.745 NZD, according to NZX as of 05/13/2026. Dividend yield was 1.682%, appealing to income-focused US investors tracking global healthcare.

Industry trends and competitive position

The global medtech market grows amid aging populations and respiratory disease prevalence, with noninvasive ventilation demand rising. Fisher & Paykel Healthcare holds a strong position in humidified high-flow therapy, competing with ResMed and Philips. Its innovation in patient interfaces differentiates it in a consolidated sector.

US market exposure provides tailwinds from domestic healthcare spending, positioning the stock as a play on international medtech for American portfolios.

Why Fisher & Paykel Healthcare matters for US investors

Listed on NZX with NZD trading, Fisher & Paykel offers US investors access to a pure-play medtech leader via ADRs or international brokers. Its products feature prominently in US hospitals, tying performance to American healthcare trends like outpatient shifts and chronic respiratory care.

Conclusion

Fisher & Paykel Healthcare Corp Ltd experienced a modest decline on May 13, 2026, reflecting market softness while maintaining solid trading activity. Fundamentals like high P/E and dividend yield underscore its medtech positioning. US investors monitor its global reach and US healthcare ties amid sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.